Published in final edited form as:

J Pediatr. 2014 March ; 164(3): 661–663. doi:10.1016/j.jpeds.2013.11.002.

Superior Mesenteric Artery Blood Flow Velocities Following Medical Treatment of a Patent Ductus Arteriosus

Toby Debra Yanowitz, MD, MS¹, Jeff Reese, MD², Maria Gillam-Krakauer, MD², Caitlin M. Cochran, MS³, Priya Jegatheesan, MD⁴, John Lau, MD⁵, Vy Thao Tran, MD⁵, Michele Walsh, MD⁶, William A. Carey, MD⁷, Alan Fuji, MD⁸, Anthony Fabio, PhD, MPH⁹, and Ronald Clyman, MD^{10,11}

¹Department of Pediatrics, University of Pittsburgh, Pittsburgh PA

⁹Department of Epidemiology, University of Pittsburgh, Pittsburgh PA

²Department of Pediatrics, Vanderbilt University, Nashville, TN

³Department of Radiology, Vanderbilt University, Nashville, TN

⁴Department of Pediatrics, Santa Clara Valley Medical Center, San Jose, CA

⁵Department of Radiology, Santa Clara Valley Medical Center, San Jose, CA

⁶Department of Pediatrics, Case Western Reserve University, Cleveland, OH

⁷Department of Pediatrics, Mayo Clinic, Rochester, MN

⁸Department of Pediatrics, Boston University Medical Center, Boston, MA

¹⁰Department of Pediatrics, University of California San Francisco, San Francisco, CA

¹¹Cardiovascular Research Institute, University of California San Francisco, San Francisco, CA

Abstract

We examined superior mesenteric artery (SMA) blood flow velocity (BFV) in response to feeding in babies randomized to trophic feeds (n=16) or *nil per os* (NPO, n=18) during prior treatment for patent ductus arteriosus. BFV increased earlier in fed babies, but was similar between groups at 30 minutes post-feed.

Keywords

not in title: Premature Infants

© 2013 Mosby, Inc. All rights reserved.

Corresponding Author: Toby Debra Yanowitz, MD. University of Pittsburgh School of Medicine. 300 Halket Street, Pittsburgh, PA 15213. Phone: 412-641-6260, fax: 412-641-5313; yanotd@mail.magee.edu.

The authors declare no conflicts of interest.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

The medical literature offers very little insight into whether it is safe to feed infants during treatment of a patent ductus arteriosus (PDA). One reason for not feeding is the possibility that the PDA itself¹ and the medications used to treat the PDA² may reduce superior mesenteric artery (SMA) blood flow and impair the ability of the infant to mount the appropriate postprandial hyperemia³ (the increase in SMA blood flow that follows a bolus feeding and is thought to enable normal digestion). On the other hand, withholding enteral nutrition for even short periods of time potentially may result in gut atrophy⁴ and impair digestive processes. We recently conducted a randomized controlled trial which addressed whether infants should be fed or kept *nil per os* (NPO) during medical treatment of a PDA. Infants were randomized to trophic feeds or NPO during indomethacin or ibuprofen treatment⁵. As part of this parent trial, we tested the hypothesis that feeding infants during PDA treatment will improve the infants' hemodynamic response to subsequent enteral nutrition. We report the results of this ancillary hemodynamic study.

METHODS

This study was approved by the IRB at each participating institution. Infants in the parent study who were born at Boston Medical Center, Case Western Reserve University Medical Center, Mayo Clinic, University of Pittsburgh Medical Center, Santa Clara Valley Medical Center, and Vanderbilt University Medical Center were eligible to participate if the parents provided written informed consent.

Details of the inclusion/exclusion criteria, randomization and masking process can be found in the parent study manuscript⁵. Eligible infants were 23^{1/7}–30^{6/7} weeks' gestation, 401–1250 grams at birth, received maximum enteral volumes of 60 mL/kg/d prior to study entry, and were about to be treated for a PDA. Infants were initially randomized to ibuprofen or indomethacin (infused over 30–50 minutes to minimize effects on mesenteric BFV⁶) and then to “feeding” (15 mL/kg/day bolus feeds) or “NPO” during the “drug treatment period”, which began with the first dose of study drug and ended 24 hours after the last dose. At the end of the drug treatment period (18–24 hours after the last dose of study drug and 3 hours after the last trophic feed for the “feeding” group), babies had a baseline mesenteric flow study. Infants were then given a test feed of 4 mL/kg and the Doppler flow study was repeated 10 and 30 minutes later.

Doppler ultrasound of SMA blood flow velocity (BFV) was obtained using a 7.5 MHz linear transducer to identify the superior mesenteric artery just distal to its origin, and a 5.0–12 MHz transducer for Doppler recording as previously described.⁷ Angle correction of up to 30° was acceptable. Systolic, mean and end-diastolic SMA BFVs were recorded through two cycles of at least 3 consecutive waves. BFVs were averaged within each cycle, and the higher cycle average was used for statistical calculations.

Data was analyzed using Student t-test, Chi-Square or Fisher Exact, and the Mann-Whitney u-test as appropriate.

RESULTS

Infants were randomized to “feeding” (n=16) or “NPO” (n=18) during the study drug treatment period. Demographic variables were similar in the two groups with the exception of preterm rupture of membranes (Table). Babies in the “feeding” group also tended to have received higher feeding volumes prior to enrollment (Table; $p=0.051$).

There were no significant differences between the “feeding” and “NPO” groups in either the baseline or post-feed SMA flow velocities (Figure). Both groups had similar and significant increases in systolic, mean, and diastolic SMA BFVs by 30 minutes after the test feed. However, infants in the “feeding” group started to increase their systolic and mean BFVs earlier after the test feed than infants in the “NPO” group (Figure). The response to feeding was not significantly different for the one baby in each group who received ibuprofen compared with babies in the same group who received indomethacin.

DISCUSSION

The “parent” trial found that infants who receive “trophic” enteral feedings, while they receive drug treatment for a PDA, require less time to reach near-full enteral nutrition. Prior studies have shown that the SMA’s postprandial BFV response can predict feeding tolerance in preterm infants⁸. Therefore, we designed an ancillary study to determine if “trophic” feedings during PDA treatment also improve postprandial hemodynamic responses during the post-treatment period.

In our study, more than 90% of the infants were treated with indomethacin. We had planned to examine an equal number of infants treated with indomethacin and ibuprofen. However, due to manufacturing problems, ibuprofen was unavailable for the majority of the study. Bolus indomethacin reduces SMA BFV for 2–4 hours after administration.² Slow infusion of indomethacin has minimal effect on mesenteric BFVs⁶. We eliminated any interfering effects of drug treatment on our study groups’ postprandial hyperemic responses by both administering the drug slowly over 30–50 minutes and also waiting 18–24 hours after the last dose before testing the infants.

Infants who were fed during the drug administration period appeared to have an earlier rise in postprandial SMA BFVs compared with those kept NPO. However, the magnitude of the postprandial hemodynamic response was similar between the groups. Additionally, despite recent PDA and PDA treatment, the baseline BFV and the BFV responses to feeding were similar in magnitude to those we reported previously in anemic preterm infants⁷. The findings support the results of the parent clinical trial⁵ in which there was no significant difference between the groups when feeding intolerance was examined in a multivariate model that included all of the relevant demographic risk factors ($P=0.1$)⁵. Importantly, there were also no differences in the incidence of necrotizing enterocolitis or spontaneous ileal perforation between groups.

In conclusion, very low birth weight infants treated medically for a PDA can mount an appropriate SMA BFV response to feeding whether they are fed trophic feeds or kept NPO during PDA treatment.

Acknowledgments

Supported by the Gerber Foundation and a gift from the Jamie and Bobby Gates Foundation.

Abbreviations

SMA	superior mesenteric artery
BFV	blood flow velocity
PDA	patent ductus arteriosus

References

1. Shimada S, Kasai T, Hoshi A, Murata A, Chida S. Cardiocirculatory effects of patent ductus arteriosus in extremely low-birth-weight infants with respiratory distress syndrome. *Pediatr Int*. 2003; 45:255–62. [PubMed: 12828577]
2. Van Bel F, Van Zoeren D, Schipper J, Guit GL, Baan J. Effect of indomethacin on superior mesenteric artery blood flow velocity in preterm infants. *J Pediatr*. 1990; 116:965–70. [PubMed: 2112189]
3. McCurnin D, Clyman RI. Effects of a patent ductus arteriosus on postprandial mesenteric perfusion in premature baboons. *Pediatrics*. 2008; 122:e1262–7. [PubMed: 19001037]
4. Hernandez G, Velasco N, Wainstein C, Castillo L, Buggedo G, Maiz A, et al. Gut mucosal atrophy after a short enteral fasting period in critically ill patients. *J Crit Care*. 1999; 14:73–7. [PubMed: 10382787]
5. Clyman R, Wickremasinghe A, Jhaveri N, Hassinger DC, Attridge JT, Sanocka U, et al. Enteral Feeding during Indomethacin and Ibuprofen Treatment of a Patent Ductus Arteriosus. *J Pediatr*. 2013 S0022-3476(13)00132-7. 10.1016/j.jpeds.2013.01.057
6. Coombs RC, Morgan MEI, Durbin GM, Booth IW, McNeish AS. Gut blood flow velocities in the newborn: effects of patent ductus arteriosus and parenteral indomethacin. *Archives of Disease in Childhood*. 1990; 65:1067–71. [PubMed: 2241229]
7. Krimmel G, Baker R, Yanowitz TD. Blood transfusion alters superior mesenteric artery blood flow response to feedings in premature infants. *Am J Perinatol*. 2009; 26:99–106. [PubMed: 19021097]
8. Fang S, Kempley ST, Gamsu HR. Prediction of early tolerance to enteral feeding in preterm infants by measurement of superior mesenteric artery blood flow velocity. *Archives of Disease in Childhood Fetal & Neonatal Edition*. 2001; 85:F42–5. [PubMed: 11420321]

Figure.

Max systolic, mean, and end-diastolic BFV for babies fed (hatched bars) and NPO (open bars) during medical treatment of the PDA. By 30 minutes after the test feed, both groups had a significant increase in systolic, mean and end-diastolic mesenteric BFV. Babies who fed during treatment of the PDA had an earlier rise in systolic and mean mesenteric BFV.

Table**Baseline Demographic and Clinical Variables**

	Fed Group (n=16)	NPO Group (n=18)	p-Value
Gestational age (weeks)	26.3 ± 1.8	26.4 ± 2.0	0.868
Birth weight (grams)	908 ± 160	923 ± 220	0.829
Sex (% female)	10 (59)	7 (41)	0.167
Race (% Caucasian)	8 (44)	10 (56)	0.746
Chorioamnionitis	3 (19)	6 (33)	0.332
Preterm rupture of membranes	16 (100)	14 (78)	0.018
Prolonged rupture of membranes	5 (31)	6 (33)	0.897
Preeclampsia	0 (0)	1 (6)	1.000
Betamethasone (any/complete course)	11 (69)/3 (19)	14 (78)/7 (39)	0.552/0.193
Apgar Score at 5 minutes	6.5 (5, 8)	6.5 (5, 8)	0.972
Respiratory Distress Syndrome	15 (94)	16 (89)	0.614
Vasopressors prior to study	0 (0)	1 (6)	1.000
Prophylactic Indomethacin	7 (44)	6 (33)	0.533
Drug for PDA treatment (indomethacin)	15 (94)	17 (94)	1.000
Volume of feed pre-study (ml/kg/day)	18.6 ± 21.7	6.7 ± 11.8	0.051
Age at Doppler study (days)	9 (8, 12)	10 (7, 13)	0.756
Postmenstrual age at study(weeks)	27.8 ± 2.28	27.8 ± 1.6	0.985
Weight at Doppler study (grams)	955 ± 222	921 ± 242	0.676
Volume used for test feed (ml)	3.2 ± 1.2	3.1 ± 1.1	0.616
Time: last PDA drug to Doppler study (hr)	20.5 ± 7.0	30.5 ± 25.6	0.128
Time: test feed to first post-feed study (min)	10.1 ± 0.5	12.1 ± 5.0	0.133
Time: test feed to 2 nd post-feed study (min)	30.3 ± 1.3	32.3 ± 6.4	0.246
Heart Rate pre-study (beats/min)	157 ± 11	159 ± 13	0.686
Mean BP pre-study (mmHg)	41 ± 9	43 ± 11	0.437
O2 Sat pre-study (%)	93 ± 6	93 ± 5	0.995
Baseline Max Systolic BFV (cm/sec)	77.4 ± 26.1	71.5 ± 20.5	0.467
Baseline Mean BFV (cm/sec)	33.8 ± 15.5	31.8 ± 10.5	0.648
Baseline End-Diastolic BFV (cm/sec)	11.3 ± 5.6	15.3 ± 9.8	0.157
Baseline Resistance Index *	0.84 ± 0.10	0.79 ± 0.11	0.116
Baseline Pulsatility Index †	2.14 ± 0.78	1.87 ± 0.57	0.258

t-test for continuous variables, Data: mean±SD; Chi-Square or Fisher Exact Test for counts, as appropriate, Data: n(%); Mann-Whitney for ordinal variables, Data: median (Q1–Q3);

* Resistance index [(systolic-diastolic BFV)/systolic BFV];

† Pulsatility index [(systolic-diastolic BFV)/mean BFV]